LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
German Shares Cheer Likelihood of September ECB Rate Cut MT
Merck Gets EU Approval for Keytruda Cancer Therapy DJ
Merck KGaA Doses First Patient in Late-stage Myasthenia Gravis Study MT
Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis CI
Chemical and pharmaceutical industry: research spending to remain virtually stable DP
Merck KGaA Plans EUR800 Million Issuance of Subordinated Hybrid Instruments MT
JPMorgan rates Merck KGaA at 'Overweight' - Target 190 euros DP
MERCK KGAA : JP Morgan maintains a Buy rating ZD
Bernstein: Sanofi Set to Record Growth on Expected Multiple Sclerosis Boost MT
Biotech firm Recursion to buy smaller peer Exscientia for $688 million RE
MERCK KGAA : UBS raises price target CF
MERCK KGAA : Receives a Buy rating from UBS ZD
MERCK KGAA : Gets a Buy rating from Deutsche Bank ZD
MERCK KGAA : DZ Bank reaffirms its Buy rating ZD
MERCK : All lights are green for a robust H2 Alphavalue
Global markets live: Shell, Chevron, Boeing, Walt Disney, Qualcomm... Our Logo
Germany's Merck KGaA Wraps Up Acquisition of US-based Mirus Bio MT
Merck KGaA increases sales - Semiconductors and Pharmaceuticals provide support DP
Transcript : Merck KGaA, Q2 2024 Earnings Call, Aug 01, 2024
MERCK KGAA : Jefferies gives a Buy rating ZD
MERCK KGAA : UBS reiterates its Buy rating ZD
MERCK KGAA : Gets a Buy rating from Barclays ZD
MERCK KGAA : Deutsche Bank remains its Buy rating ZD
MERCK KGAA : JP Morgan reiterates its Buy rating ZD
Merck reports earlier-than-expected improvement in semiconductor market RE
Chart Merck KGaA
More charts
Logo Merck KGaA
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Employees
62,176
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
169.90EUR
Average target price
185.94EUR
Spread / Average Target
+9.44%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck KGaA
  5. Germany's Merck KGaA Wraps Up Acquisition of US-based Mirus Bio
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW